Overview

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Status:
Terminated
Trial end date:
2013-03-11
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo, Inc.
Plexxikon
Collaborator:
Plexxikon